President Trump Expected to Announce Nationwide Medicaid Drug Pricing Program

Clarksburg Weston, WV, September 18, 2026 — The Trump administration is reportedly preparing to announce a significant initiative aimed at reducing prescription drug costs for Medicaid recipients. President Donald Trump is expected to reveal that all 50 United States will participate in a new drug pricing program.

This program is designed with the stated goal of lowering the net cost of selected medications across the nation. The mechanism intended to achieve this reduction is the implementation of a “most favored nation” pricing policy. This approach typically involves tying the prices paid for drugs in a particular country to the lowest prices paid for the same drugs in other developed nations.

The specifics of the program’s rollout and the exact list of medications to be covered were not detailed in the initial information. Similarly, the timeline for when states would officially join or when the pricing changes would take effect was not provided. The program’s focus is on the Medicaid drug pricing structure, a significant component of the U.S. healthcare system that provides coverage to millions of Americans.

A “most favored nation” clause in pricing agreements generally ensures that a buyer receives the best price offered by a seller to any other buyer. Applying this principle to a national scale, particularly within a government healthcare program like Medicaid, could potentially lead to substantial changes in how pharmaceutical companies price and distribute their products. The expected announcement marks a key development in the administration’s ongoing efforts to address drug affordability.

Story summarized from the original created by FATIMA HUSSEIN, Associated Press on www.wboy.com, see more information here.

Media gallery